A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

Part of paid clinical trials in Anaheim, California.

Sponsor
AbbVie
Study ID
NCT07414784
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • ABBV-295 — DRUG
    Subcutaneous Injections
  • Levonorgestrel/Ethinyl Estradiol — DRUG
    Oral Tablet

Study Details

This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.

Key Dates

Start date
Feb 11, 2026
Status verified
Apr 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ABBV-295 with Levonorgestrel and Ethinyl Estradiol
    Participants will receive subcutaneous doses of ABBV-295 with levonorgestrel and ethinyl estradiol for 68 days.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to approximately 128 days ]

Locations (2)

FacilityCityStateZIPSite coordinators
CenExel ACT- Anaheim Clinical Trials /ID# 281863AnaheimCalifornia92801-
Acpru /Id# 280538GrayslakeIllinois60030-

Find similar trials in Anaheim, CA

By research site
CenExel ACT- Anaheim Clinical Trials· Anaheim, CAAcpru· Grayslake, IL

Related Studies